Congratulations to Dr. Robert Lukowski who was appointed as Full Professor of Experimental Pharmacology in the Pharmacology, Toxicology and Clinical Pharmacy Department at the University of Tübingen. His research focuses on the impact of cGMP pathway modulation and Ca2+/Na+-activated K+ channels such as BK and Slo2.2/Slack in animal models of disease and their utility in drug discovery applications. Since 2013 he acts as training coordinator and speaker of ICEPHA´s Graduate Program and as a board member of the DFG Research Unit “cGMP Signaling in Cell Growth and Survival” (FOR 2060).
To learn more about Robert Lukowski follow the link to the Experimental Pharmacology group at the Institute of Pharmacy.
ICEPHA´s speakers Prof. Laufer and Prof. Schwab, together with other renowned experts, contribute with their unique know-how, techniques and tools to the division of "Therapy Design" within the University of Tübingen framework of the Excellence Initiative. Find more information about "Therapy Design" within platform one of the University´s Excellence Initiative on personalised medicine.
The ICEPHA has established a preferred partnership with the Tübingen Center for Academic Drug Discovery & Development (TüCAD2). Together with this academic platform we will optimize the development of potential drug candidates and their utility for clinical application. To learn more about TüCAD2, its members and projects please follow the link to the University´s Excellence Initiative.
Second call for the ICEPHA Graduate Program (more information will follow in May 2018).